Breaking News Instant updates and real-time market news.

TODAY'S FREE FLY STORIES

Downgrade
Jefferies 'underwhelmed' by CytomX presentations at ASCO, downgrades to Hold » 08:14
06/01/20
06/01
08:14
06/01/20
08:14
CTMX

CytomX Therapeutics

$8.86 /

+0.13 (+1.49%)

As previously reported,…

As previously reported, Jefferies analyst Biren Amin downgraded CytomX Therapeutics to Hold from Buy with a price target of $10, down from $16. Amin was "underwhelmed across the board" by the multiple presentations at ASCO regarding CytomX Therapeutics' clinical stage pipeline programs and partnered pipeline, the analyst tells investors. Of key investor interest, data for CX-2029 suggests a narrow therapeutic index and raises concerns about safety issues, the analyst added. Amin also sees "a lack of clear strategy" for CX-072 and a "challenging" path for CX-2009.

ShowHide Related Items >><<
CTMX CytomX Therapeutics
$8.86 /

+0.13 (+1.49%)

CTMX CytomX Therapeutics
$8.86 /

+0.13 (+1.49%)

06/01/20 Jefferies
CytomX Therapeutics downgraded to Hold from Buy at Jefferies
05/29/20 Piper Sandler
CytomX ASCO data sets point torwards Probody validation, says Piper Sandler
05/14/20 H.C. Wainwright
CytomX Therapeutics price target lowered to $12 from $16 at H.C. Wainwright
05/08/20 H.C. Wainwright
CytomX Therapeutics price target raised to $16 from $14 at H.C. Wainwright
CTMX CytomX Therapeutics
$8.86 /

+0.13 (+1.49%)

CTMX CytomX Therapeutics
$8.86 /

+0.13 (+1.49%)

Hot Stocks
NMI Holdings enters into quota share reinsurance arrangement » 08:13
06/01/20
06/01
08:13
06/01/20
08:13
NMIH

NMI Holdings

$15.40 /

-0.09 (-0.58%)

NMI Holdings has entered…

NMI Holdings has entered into a new quota share reinsurance arrangement, subject to customary approvals, with a broad panel of highly rated reinsurers. Under the new agreement, National MI will cede, subject to certain limitations, exclusions, and conditions, 10.5% of its primary new insurance written for the period from April 1, 2020 through December 31, 2020. The ceded percentage may be increased with additions to the reinsurance panel. The company will receive a ceding commission equal to 20% of ceded premiums, as well as a profit commission of up to 50% of ceded premiums, reduced by any losses ceded under the agreement.

ShowHide Related Items >><<
NMIH NMI Holdings
$15.40 /

-0.09 (-0.58%)

NMIH NMI Holdings
$15.40 /

-0.09 (-0.58%)

04/06/20 B. Riley FBR
Fannie, Freddie downgraded to Sell with $1 targets at B. Riley FBR
03/26/20 RBC Capital
NMI Holdings price target lowered to $18 from $38 at RBC Capital
03/11/20 B. Riley FBR
B. Riley FBR downgrades CNO Financial, Progressive to Neutral from Buy
03/09/20 Barclays
NMI Holdings shares are 'too cheap,' says Barclays
NMIH NMI Holdings
$15.40 /

-0.09 (-0.58%)

Conference/Events
General Motors management to meet virtually with Wolfe Research » 08:13
06/01/20
06/01
08:13
06/01/20
08:13
GM

General Motors

$25.87 /

-0.81 (-3.04%)

Wolfe Research holds a…

Wolfe Research holds a virtual fireside chat with CEO Barra and CFO Suryadevara on June 3 at 1pm.

ShowHide Related Items >><<
GM General Motors
$25.87 /

-0.81 (-3.04%)

GM General Motors
$25.87 /

-0.81 (-3.04%)

05/19/20 Argus
General Motors EPS view cut at Argus
05/11/20 Nomura Instinet
General Motors price target lowered to $23 from $36 at Nomura Instinet
05/08/20 Jefferies
Jefferies prefers Ford although GM resilience put it 'to shame' in Q1
05/07/20
Fly Intel: Top five analyst upgrades
GM General Motors
$25.87 /

-0.81 (-3.04%)

GM General Motors
$25.87 /

-0.81 (-3.04%)

GM General Motors
$25.87 /

-0.81 (-3.04%)

GM General Motors
$25.87 /

-0.81 (-3.04%)

Hot Stocks
Histogen doses first patient in Phase 1b/2a trial of HST 001 » 08:13
06/01/20
06/01
08:13
06/01/20
08:13
HSTO

Histogen

$4.37 /

+0.085 (+1.98%)

Histogen announced the…

Histogen announced the enrollment of the first patient in its Phase 1b/2a clinical trial of HST 001, the Company's lead therapeutic candidate for the treatment of androgenic alopecia in men. This blinded, randomized, placebo controlled, single site study will enroll 36 subjects with male pattern hair loss using a 2:1 randomization HST 001 to placebo. It is designed to assess the safety and tolerability of HST 001, as well as indicators of efficacy including non-vellus hair count, total hair count, and hair thickness density as measured by Canfield macrophotography. Building on prior clinical experience with HST 001, the Phase 1b/2a study will be the first company-sponsored trial to include a third dosing timepoint, with dosing taking place at week 0, week 6 and week 12. At each treatment timepoint, subjects will receive 20 injections focused on temporal recession and vertex scalp areas, the most common regions of hair loss in men with androgenic alopecia. Top-line data is anticipated to be available in the fourth quarter of 2020.

ShowHide Related Items >><<
HSTO Histogen
$4.37 /

+0.085 (+1.98%)

HSTO Histogen
$4.37 /

+0.085 (+1.98%)

Downgrade
Oracle downgraded to Neutral from Outperform at Exane BNP Paribas » 08:12
06/01/20
06/01
08:12
06/01/20
08:12
ORCL

Oracle

$53.73 /

+0.11 (+0.21%)

Exane BNP Paribas analyst…

Exane BNP Paribas analyst Stefan Slowinski downgraded Oracle to Neutral from Outperform with a $56 price target.

ShowHide Related Items >><<
ORCL Oracle
$53.73 /

+0.11 (+0.21%)

ORCL Oracle
$53.73 /

+0.11 (+0.21%)

05/08/20 DA Davidson
SailPoint price target raised to $24 from $18 at DA Davidson
04/09/20 Jefferies
Oracle should use cash for deals over buybacks, says Jefferies
03/31/20 Exane BNP Paribas
Oracle upgraded to Outperform from Neutral at Exane BNP Paribas
03/20/20
Fly Intel: Top five analyst upgrades
ORCL Oracle
$53.73 /

+0.11 (+0.21%)

ORCL Oracle
$53.73 /

+0.11 (+0.21%)

ORCL Oracle
$53.73 /

+0.11 (+0.21%)

ORCL Oracle
$53.73 /

+0.11 (+0.21%)

Hot Stocks
Cellectar Biosciences granted SME status by EMA » 08:12
06/01/20
06/01
08:12
06/01/20
08:12
CLRB

Cellectar Biosciences

$1.55 /

+0.18 (+13.14%)

Cellectar Biosciences…

Cellectar Biosciences announced that it has been granted Small and Medium-Sized Enterprise status by the European Medicines Agency's Micro, Small and Medium-sized Enterprise office. The newly granted SME status allows Cellectar to participate in significant financial incentives that include a 90% to 100% EMA fee reduction for scientific advice, clinical study protocol design, endpoints and statistical considerations, quality inspections of facilities and fee waivers for selective EMA pre and post-authorization regulatory filings, including orphan drug and PRIME designations. Cellectar is also eligible to obtain EMA certification of quality and manufacturing data prior to review of clinical data. Other financial incentives include EMA-provided translational services of all regulatory documents required for market authorization, further reducing the financial burden of the market authorization process.

ShowHide Related Items >><<
CLRB Cellectar Biosciences
$1.55 /

+0.18 (+13.14%)

CLRB Cellectar Biosciences
$1.55 /

+0.18 (+13.14%)

02/20/20 Roth Capital
Cellectar Biosciences stock dip 'unwarranted,' says Roth Capital
01/21/20 Roth Capital
Cellectar Biosciences transferred at Buy at Roth Capital
10/01/19 Roth Capital
Roth Capital reiterates Buy rating on Cellectar after ESMO meeting
09/13/19 Roth Capital
Cellectar Biosciences initiated with a Buy at Roth Capital
CLRB Cellectar Biosciences
$1.55 /

+0.18 (+13.14%)

Hot Stocks
Enphase Energy collaborates with SmartX » 08:10
06/01/20
06/01
08:10
06/01/20
08:10
ENPH

Enphase Energy

$58.08 /

+2.3 (+4.12%)

Enphase Energy announced…

Enphase Energy announced its expansion into Poland through a collaboration with SmartX Sp. z o.o., a solar distributor with headquarters in Bytom, Poland. Currently, Poland has one of the top five solar markets in Europe, with an estimated installed capacity of more than 1 GW. SmartX's installer network throughout Poland offers both residential and small commercial microinverter systems, utilizing Enphase IQ 7 family of microinverters including IQ 7, IQ 7+ and IQ 7X. In addition, SmartX's residential solar systems are outfitted with Enphase Envoy communications gateways, which connect an Enphase-based solar system to the Enphase Enlighten monitoring platform and helps make per-panel energy monitoring and insights for operations and maintenance easy.

ShowHide Related Items >><<
ENPH Enphase Energy
$58.08 /

+2.3 (+4.12%)

ENPH Enphase Energy
$58.08 /

+2.3 (+4.12%)

05/28/20 JPMorgan
Enphase Energy price target raised to $67 from $54 at JPMorgan
05/27/20 Johnson Rice
Johnson Rice starts Enphase Energy with Accumulate, $68 price target
05/27/20 Johnson Rice
Enphase Energy initiated with an Accumulate at Johnson Rice
05/14/20
Fly Intel: Top five analyst downgrades
ENPH Enphase Energy
$58.08 /

+2.3 (+4.12%)

ENPH Enphase Energy
$58.08 /

+2.3 (+4.12%)

ENPH Enphase Energy
$58.08 /

+2.3 (+4.12%)

Hot Stocks
Flexsteel Industries announces $6M stock repurchase program » 08:10
06/01/20
06/01
08:10
06/01/20
08:10
FLXS

Flexsteel Industries

$9.92 /

-0.37 (-3.60%)

The board authorized a…

The board authorized a stock repurchase program under which the company may repurchase up to $6M of its outstanding common shares. The company said the board determined that a modest stock buy-back program could help mitigate undue pressure on the stock given the uncertainty of the Russell reconstitution, while not jeopardizing business plans and debt covenants. The repurchase program is authorized to last through June 9, 2021.

ShowHide Related Items >><<
FLXS Flexsteel Industries
$9.92 /

-0.37 (-3.60%)

Conference/Events
U.S. Physical Therapy management to meet virtually with Barrington » 08:10
06/01/20
06/01
08:10
06/01/20
08:10
USPH

U.S. Physical Therapy

$74.19 /

-1.38 (-1.83%)

Virtual Meetings to be…

Virtual Meetings to be held June 3-4 hosted by Barrington.

ShowHide Related Items >><<
USPH U.S. Physical Therapy
$74.19 /

-1.38 (-1.83%)

USPH U.S. Physical Therapy
$74.19 /

-1.38 (-1.83%)

04/30/20 Sidoti
U.S. Physical Therapy downgraded to Neutral following run-up at Sidoti
04/30/20 Sidoti
U.S. Physical Therapy downgraded to Neutral from Buy at Sidoti
03/11/20 Sidoti
U.S. Physical Therapy upgraded to Buy from Neutral at Sidoti
02/28/20 Barrington
U.S. Physical Therapy selloff brings good entry point, says Barrington
USPH U.S. Physical Therapy
$74.19 /

-1.38 (-1.83%)

Hot Stocks
Diffusion Pharmaceuticals regains compliance with Nasdaq requirement » 08:09
06/01/20
06/01
08:09
06/01/20
08:09
DFFN

Diffusion Pharmaceuticals

$1.30 /

+0.01 (+0.78%)

Diffusion Pharmaceuticals…

Diffusion Pharmaceuticals announces that on May 29, 2020 it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market, stating that the Company regained compliance with the applicable Nasdaq minimum bid price continued listing standard and the matter is now closed. The Company had previously been notified by Nasdaq on December 11, 2019 that it was not in compliance with the minimum bid price rule because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. In order to regain compliance with Listing Rule 5550(a)(2), the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved on May 28, 2020. The Company's last closing bid price on May 28 was $1.27. This development means that while the Company is still seeking authority from its stockholders for a reverse split of the Company's common stock, it is not currently anticipated that the board will implement a reverse split at this time, absent a change in the market price of the Company's common stock.

ShowHide Related Items >><<
DFFN Diffusion Pharmaceuticals
$1.30 /

+0.01 (+0.78%)

DFFN Diffusion Pharmaceuticals
$1.30 /

+0.01 (+0.78%)

12/18/19 H.C. Wainwright
Diffusion price target lowered to $3.50 from $10 at H.C. Wainwright
Hot Stocks
Mudrick Capital Acquisition acquires Hycroft Mining » 08:09
06/01/20
06/01
08:09
06/01/20
08:09
MUDS

Mudrick Capital Acquisition

/

+

Mudrick Capital…

Mudrick Capital Acquisition and Hycroft Mining, a U.S.-based, gold and silver producer in Nevada, are pleased to announce the consummation of the purchase of Hycroft by MUDS. The shareholders of each of MUDS and Hycroft approved the transaction, which closed on May 29, creating a new world-class mining company named Hycroft Mining Holding that will trade publicly on the NASDAQ Capital Market under the ticker symbol "HYMC." Hycroft has sold all of the equity interests of Hycroft's subsidiaries and substantially all of its other assets to MUDS, and MUDS has discharged and paid or assumed all or substantially all of Hycroft's liabilities. HYMC has 50.2M common shares outstanding, as of the consummation of the transaction.

ShowHide Related Items >><<
MUDS Mudrick Capital Acquisition
/

+

Periodicals
United Airlines to cut 13 officer positions, Reuters reports » 08:09
06/01/20
06/01
08:09
06/01/20
08:09
UAL

United Airlines

$28.01 /

-0.88 (-3.05%)

United Airlines will cut…

United Airlines will cut 13 of its officer positions as part of a restructuring and add some international flights back to its network in July, Reuters' Tracy Rucinski reports. United is preparing for management and administrative staff to be at least 30% smaller in October, when a government-imposed ban on job cuts expires for companies that have received payroll aid under the CARES Act. Reference Link

ShowHide Related Items >><<
UAL United Airlines
$28.01 /

-0.88 (-3.05%)

UAL United Airlines
$28.01 /

-0.88 (-3.05%)

05/26/20 Citi
Lufthansa bailout 'marginally positive' for United Airlines,says Citi
05/19/20 Goldman Sachs
Southwest, United seeing modest improvements in demand, says Goldman Sachs
05/04/20 Barclays
Barclays downgrades U.S. Airlines sector along with American and Delta
05/04/20 Barclays
United Airlines price target lowered to $40 from $60 at Barclays
UAL United Airlines
$28.01 /

-0.88 (-3.05%)

UAL United Airlines
$28.01 /

-0.88 (-3.05%)

UAL United Airlines
$28.01 /

-0.88 (-3.05%)

UAL United Airlines
$28.01 /

-0.88 (-3.05%)

Recommendations
Repay Holdings price target raised to $27 from $20 at Keefe Bruyette » 08:09
06/01/20
06/01
08:09
06/01/20
08:09
RPAY

Repay Holdings

$22.98 /

+2.35 (+11.39%)

Keefe Bruyette analyst…

Keefe Bruyette analyst Sanjay Sakhrani raised the firm's price target on Repay Holdings to $27 from $20 and keeps an Outperform rating on the shares. The analyst a higher multiple is warranted given the company's optionality from potential acquisition deals following its recent equity raise. While initially dilutive to earnings, the equity raise should be accretive over the longer term as Repay deploys the proceeds toward accretive deals that should help support its "strong earnings growth trajectory," Sakhrani tells investors in a research note.

ShowHide Related Items >><<
RPAY Repay Holdings
$22.98 /

+2.35 (+11.39%)

RPAY Repay Holdings
$22.98 /

+2.35 (+11.39%)

05/19/20 BTIG
Repay Holdings price target raised to $25 from $20 at BTIG
04/17/20
Fly Intel: Top five analyst initiations
04/17/20 DA Davidson
Repay Holdings initiated with a Buy at DA Davidson
03/17/20 Canaccord
Repay Holdings outlook could be helped by current environment, says Canaccord
RPAY Repay Holdings
$22.98 /

+2.35 (+11.39%)

RPAY Repay Holdings
$22.98 /

+2.35 (+11.39%)

Hot Stocks
Delta 9 Cannabis completes transaction to acquire two Alberta stores » 08:09
06/01/20
06/01
08:09
06/01/20
08:09
VRNDF

Delta 9 Cannabis

$0.00 /

+ (+0.00%)

DELTA 9 CANNABIS announce…

DELTA 9 CANNABIS announce dthat on May 29, 2020 it closed a transaction with Modern Leaf Group to acquire all or substantially all of Modern Leaf's assets located in the Province of Alberta relating to two retail cannabis stores located in Calgary, Alberta and Grande Prairie, Alberta. The acquisition is being completed through the Company's wholly-owned subsidiary, Delta 9 Cannabis Store Inc., and pursuant to the previously announced purchase agreement among Delta 9 Cannabis Store Inc., Modern Leaf and Mr. Preston Drummond dated November 21, 2019. Kronos Capital Partners advised Modern Leaf in regards to the transaction. The purchase price paid by Delta 9 Cannabis Store Inc. relating to the Transaction was $1,300,000, subject to customary adjustments. $1,000,000 of the Purchase Price was satisfied through the issuance of 1,250,000 common shares in the capital stock of the Company, a price per Common Share of $0.80 based on the closing market price of the Common Shares on the Toronto Stock Exchange on September 19, 2019, such date being the date that the Company and Modern Leaf entered into a previously announced binding letter of intent with respect to the Proposed Transaction. The balance of the Purchase Price was paid by way of the release of the $150,000 deposit in respect of the transaction, and the payment of $150,000, satisfied in cash. Upon the closing of the Transaction under the Agreement, Delta 9 Cannabis Store Inc. and Modern Leaf entered into additional agreements effective at the date of closing providing for, among other things, the granting of a right of first refusal by Modern Leaf in favour of Delta 9 Cannabis Store Inc. pertaining to the purchase of a retail cannabis store located in Olds, Alberta and the granting of certain restrictive covenants by Modern Leaf in favour of Delta 9 Cannabis Store Inc. The final closing of the Transaction remains subject to the approval of the Toronto Stock Exchange.

ShowHide Related Items >><<
VRNDF Delta 9 Cannabis
$0.00 /

+ (+0.00%)

VRNDF Delta 9 Cannabis
$0.00 /

+ (+0.00%)

05/20/20 Canaccord
Delta 9 Cannabis upgraded to Speculative Buy from Hold at Canaccord
VRNDF Delta 9 Cannabis
$0.00 /

+ (+0.00%)

VRNDF Delta 9 Cannabis
$0.00 /

+ (+0.00%)

Hot Stocks
Flexsteel Industries implements conservative cash strategies amid COVID-19 » 08:08
06/01/20
06/01
08:08
06/01/20
08:08
FLXS

Flexsteel Industries

$9.92 /

-0.37 (-3.60%)

Flexsteel Industries…

Flexsteel Industries announced that, in light of the continued economic uncertainty and dampened demand for furniture related to COVID-19, the company and its board have implemented conservative cash strategies to ensure the viability of the company and to maximize its financial flexibility until economic conditions stabilize. The company has extended 25% salary reductions for the CEO and CFO/COO and 50% cash compensation reduction for the board through October 1. Flexsteel is also evaluating and renegotiating company lease obligations where feasible. Lastly, the company has gained a commitment from Dubuque Bank & Trust for a new secured $45M credit facility with a two-year term. On April 28, the company announced its intent to exit the recreational vehicle seating and remaining hospitality businesses after determining they were no longer strategic to the future of the company. As a result of these planned actions, the company anticipates incurring pre-tax restructuring and related expenses between $25M and $28M, with a majority of expenses to be incurred in Q4. Cash charges are expected to be between $3M to $5M, and non-cash charges, including asset impairments, are expected to be between $22M and $23M.

ShowHide Related Items >><<
FLXS Flexsteel Industries
$9.92 /

-0.37 (-3.60%)

Hot Stocks
HCI Group headquarters to be acquired by State of Florida » 08:07
06/01/20
06/01
08:07
06/01/20
08:07
HCI

HCI Group

$44.59 /

-1.01 (-2.21%)

Greenleaf Capital, LLC,…

Greenleaf Capital, LLC, the real estate division of HCI Group, has entered into an agreement with the Florida Department of Transportation by which the State of Florida will acquire HCI's headquarters property and a nearby right of way in connection with a planned road improvement project. The combined compensation to Greenleaf for the acquisitions is set at $47.5M. After transaction costs, Greenleaf expects to net approximately $44M. The property, known as "Cypress Commons," is located at 5300 West Cypress Street in Tampa. The transaction is expected to conclude by the end of July 2020. As part of the agreement, HCI has the option to occupy the headquarters property for up to three years after the acquisition. During this time, Greenleaf will continue to manage the property, which has numerous tenants.

ShowHide Related Items >><<
HCI HCI Group
$44.59 /

-1.01 (-2.21%)

HCI HCI Group
$44.59 /

-1.01 (-2.21%)

Conference/Events
R1 RCM management to meet virtually with Cantor Fitzgerald » 08:07
06/01/20
06/01
08:07
06/01/20
08:07
RCM

R1 RCM

$10.63 /

-0.11 (-1.02%)

Virtual Meeting to be…

Virtual Meeting to be held on June 3 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
RCM R1 RCM
$10.63 /

-0.11 (-1.02%)

RCM R1 RCM
$10.63 /

-0.11 (-1.02%)

04/20/20 RBC Capital
R1 RCM initiated with an Outperform at RBC Capital
04/13/20 SVB Leerink
R1 RCM initiated with a Market Perform at SVB Leerink
03/26/20 Cowen
Cowen sees three healthcare IT names poised for rebound
01/21/20 Cantor Fitzgerald
R1 RCM price target raised to $17 from $15 at Cantor Fitzgerald
RCM R1 RCM
$10.63 /

-0.11 (-1.02%)

Periodicals
Energy Transfer to begin cutting about 6% of workforce, Reuters reports » 08:07
06/01/20
06/01
08:07
06/01/20
08:07
ET

Energy Transfer LP

$8.17 /

-0.095 (-1.15%)

Energy Transfer will…

Energy Transfer will begin cutting about 6% of its workforce this week, according to a recorded message to employees of the pipeline operator heard by Reuters, Shariq Khan reports. The move comes amid sinking oil and gas prices and a drop in business for companies like Energy Transfer. Reference Link

ShowHide Related Items >><<
ET Energy Transfer LP
$8.17 /

-0.095 (-1.15%)

ET Energy Transfer LP
$8.17 /

-0.095 (-1.15%)

05/13/20 Bernstein
Energy Transfer LP price target lowered to $12 from $22 at Bernstein
04/13/20 Wolfe Research
Energy Transfer LP downgraded to Peer Perform from Outperform at Wolfe Research
03/24/20 Barclays
Energy Transfer LP downgraded to Equal Weight from Overweight at Barclays
03/16/20 Morgan Stanley
Morgan Stanley shakes up Midstream ratings in expectation of continued pressure
ET Energy Transfer LP
$8.17 /

-0.095 (-1.15%)

ET Energy Transfer LP
$8.17 /

-0.095 (-1.15%)

ET Energy Transfer LP
$8.17 /

-0.095 (-1.15%)

ET Energy Transfer LP
$8.17 /

-0.095 (-1.15%)

Downgrade
Westpac downgraded to Underperform from Hold at Jefferies » 08:07
06/01/20
06/01
08:07
06/01/20
08:07
WBK

Westpac

$11.38 /

-0.675 (-5.60%)

Jefferies analyst Brian…

Jefferies analyst Brian Johnson downgraded Westpac to Underperform from Hold with a price target of A$13.34, down from A$14.30. While "derated" Australian banks are "cheaper than they were," anything other than a sharp "V" shaped economic recovery suggests further material share price downside given the risks for rising loan losses and lower dividend servicing capacity, Johnson argues.

ShowHide Related Items >><<
WBK Westpac
$11.38 /

-0.675 (-5.60%)

WBK Westpac
$11.38 /

-0.675 (-5.60%)

04/27/20 JPMorgan
Westpac downgraded to Neutral from Overweight at JPMorgan
03/24/20 JPMorgan
Westpac upgraded to Overweight from Neutral at JPMorgan
03/17/20 Jefferies
Westpac upgraded to Hold from Underperform at Jefferies
02/03/20 Morgan Stanley
Westpac downgraded to Underweight from Equal Weight at Morgan Stanley
Conference/Events
Perdoceo Education management to meet virtually with Barrington » 08:07
06/01/20
06/01
08:07
06/01/20
08:07
PRDO

Perdoceo Education

$16.28 /

-0.07 (-0.43%)

Virtual Meeting to be…

Virtual Meeting to be held on June 3 hosted by Barrington.

ShowHide Related Items >><<
PRDO Perdoceo Education
$16.28 /

-0.07 (-0.43%)

PRDO Perdoceo Education
$16.28 /

-0.07 (-0.43%)

Hot Stocks
Neoleukin Therapeutics appoints Erin Lavelle to board of directors » 08:06
06/01/20
06/01
08:06
06/01/20
08:06
NLTX

Neoleukin Therapeutics

$12.17 /

-0.01 (-0.08%)

Neoleukin Therapeutics…

Neoleukin Therapeutics announced the appointment of Erin Lavelle to the company's Board of Directors. Ms. Lavelle has more than 20 years of strategic and operational leadership experience in the biopharmaceutical industry and most recently served as COO for Alder Biopharmaceuticals, Inc. She succeeds Sean Nolan, who will be stepping down from the Board. Mr. Nolan has served as a director of Aquinox Pharmaceutics since 2015 and remained on the Neoleukin Board after the merger in August 2019.

ShowHide Related Items >><<
NLTX Neoleukin Therapeutics
$12.17 /

-0.01 (-0.08%)

NLTX Neoleukin Therapeutics
$12.17 /

-0.01 (-0.08%)

04/13/20 H.C. Wainwright
Neoleukin Therapeutics initiated with a Buy at H.C. Wainwright
03/16/20
Fly Intel: Top five analyst initiations
03/16/20 BofA
Neoleukin Therapeutics initiated with a Buy at BofA
03/12/20
Fly Intel: Top five analyst initiations
NLTX Neoleukin Therapeutics
$12.17 /

-0.01 (-0.08%)

NLTX Neoleukin Therapeutics
$12.17 /

-0.01 (-0.08%)

Syndicate
BioLineRx announces $4.39M registered direct offering » 08:06
06/01/20
06/01
08:06
06/01/20
08:06
BLRX

BioLineRx

$1.95 /

+0.23 (+13.37%)

BioLineRx announced that…

BioLineRx announced that it has entered into definitive agreements with several healthcare-focused, institutional and accredited investors for the purchase and sale of 2,510,286 of the company's American Depositary Shares, at a purchase price of $1.75 per ADS, in a registered direct offering. BioLineRx has also agreed to issue and sell to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 2,510,286 ADSs. Each ADS represents fifteen ordinary shares, par value NIS 0.10 per share, of BioLineRx. The offering is expected to close on or about June 3, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The warrants will have an exercise price of $2.25 per ADS and will be exercisable at any time upon issuance and will expire two and one-half years from the date of issuance. The gross proceeds from the offering, before deducting the placement agent's fees and other estimated offering expenses payable by the company, are expected to be $4.39M.

ShowHide Related Items >><<
BLRX BioLineRx
$1.95 /

+0.23 (+13.37%)

BLRX BioLineRx
$1.95 /

+0.23 (+13.37%)

03/13/20 Oppenheimer
BioLineRx price target lowered to $11 from $26 at Oppenheimer
BLRX BioLineRx
$1.95 /

+0.23 (+13.37%)

Conference/Events
Pegasystems management to meetvirtually with KeyBanc » 08:06
06/01/20
06/01
08:06
06/01/20
08:06
PEGA

Pegasystems

$95.13 /

+0.84 (+0.89%)

Virtual Meeting to be…

Virtual Meeting to be held on June 3 hosted by KeyBanc.

ShowHide Related Items >><<
PEGA Pegasystems
$95.13 /

+0.84 (+0.89%)

PEGA Pegasystems
$95.13 /

+0.84 (+0.89%)

05/26/20
Fly Intel: Top five analyst initiations
05/26/20 Goldman Sachs
Pegasystems initiated with a Buy at Goldman Sachs
04/30/20 Wedbush
Pegasystems price target raised to $104 from $96 at Wedbush
04/30/20 KeyBanc
Pegasystems price target lowered to $104 from $110 at KeyBanc
PEGA Pegasystems
$95.13 /

+0.84 (+0.89%)

Recommendations
Pfizer price target lowered to $35 from $37 at Barclays » 08:06
06/01/20
06/01
08:06
06/01/20
08:06
PFE

Pfizer

$38.14 /

-0.03 (-0.08%)

Barclays analyst Carter…

Barclays analyst Carter Gould lowered the firm's price target on Pfizer to $35 from $37 and keeps an Equal Weight rating on the shares. On the back of Pfizer's disclosure that the Ibrance Phase 3 PALLAS study was being stopped for futility, the analyst removed all adjuvant sales from the model, lowering his 2025 sales estimates by ~$2B, and 2020-2025 annual earnings growth estimate to 3.3% from 4.1%.

ShowHide Related Items >><<
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

Hot Stocks
Pinnacle Dermatology selects R1 RCM 's revenue cycle management solutions » 08:06
06/01/20
06/01
08:06
06/01/20
08:06
RCM

R1 RCM

$10.63 /

-0.11 (-1.02%)

R1 RCM announced Pinnacle…

R1 RCM announced Pinnacle Dermatology, one of the most prominent multi-state leaders in population skin health management, has selected R1's revenue cycle management solution to help improve performance, lower costs and increase patient satisfaction. Pinnacle Dermatology, based in Chicago, selected R1 to optimize the revenue cycle for its 50+ locations across five states and to support its significant long-term growth goals.

ShowHide Related Items >><<
RCM R1 RCM
$10.63 /

-0.11 (-1.02%)

RCM R1 RCM
$10.63 /

-0.11 (-1.02%)

04/20/20 RBC Capital
R1 RCM initiated with an Outperform at RBC Capital
04/13/20 SVB Leerink
R1 RCM initiated with a Market Perform at SVB Leerink
03/26/20 Cowen
Cowen sees three healthcare IT names poised for rebound
01/21/20 Cantor Fitzgerald
R1 RCM price target raised to $17 from $15 at Cantor Fitzgerald
RCM R1 RCM
$10.63 /

-0.11 (-1.02%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.